Extended observations on MS patients tre
✍
Lawrence Jacobs; Richard Rudick; Jack Simon
📂
Article
📅
2000
🏛
Elsevier Science
🌐
English
⚖ 82 KB
Extended observations of the pivotal phase III clinical trial of interferon-beta1a (IFNbeta1a; Avonex, Biogen) in relapsing MS patients revealed that: (1) active treatment significantly slowed the accumulation of physical disability over time, reduced clinical exacerbations and MRI brain lesions; (2